ELPEN CDMO has over 25 years of experience in the development and manufacturing of respiratory products across several OINDP categories, including DPIs, Nasals, and pMDIs, with many products introduced into multiple markets worldwide. Furthermore, we were the first to develop and market a hybrid generic version of fluticasone and salmeterol dry powder combination for the treatment of asthma and COPD.
Our capabilities range from formulation development, device development & evaluation, and analytical development to clinical batch manufacturing, commercial manufacturing, packaging, and product release. We are flexible in our collaborations, and offer IP, CMC and Regulatory support at every development stage.
We operate in two productions plants, both located in Athens, Attica, Greece. Dry powders and nasal products are developed and produced in Pikermi, whilst pMDIs are developed and produced in a state-of-the-art manufacturing facility in Keratea.
Regarding our pMDI capabilities, with our extensive expertise we can provide development, clinical, and commercial manufacturing services using all types of propellants, including green propellants HFA-152a and HFO-1234ze.
We operate according to the EU regulations, and being situated within the European Union, we offer short transportation times to European and other destinations worldwide.
Experience, quality, and flexibility drive excellence, making ELPEN CDMO the ideal partner.
ELPEN
95 Marathonos Avenue
Pikermi, Attica 19009
Greece
+30 211 1865 000
www.elpen.gr/en/
info@elpen.gr
Low-GWP pMDI Solutions: From Development to Commercial Supply
Environmentally friendly propellants are essential in reducing our industry's environmental impact. With expertise in low-GWP solutions, we assist our partners in bringing sustainable inhalation products to market. From formulation to scalable manufacturing, we ensure regulatory compliance and efficiency, all while maintaining the highest quality standards. More Info
Cutting-Edge pMDI Manufacturing Hub in Europe
Our state-of-the-art European facility is designed for next generation pMDI production, supporting both HFO-1234ze and HFA-152a based formulations. With GMP and non-GMP capabilities, we offer pilot-scale development and full commercial manufacturing, ensuring efficiency, quality, and sustainability for the future of inhalation drug delivery. More Info
Your CDMO Partner of Choice
As your pMDI CDMO partner, we offer end-to-end contract manufacturing solutions with 25 years of expertise in OINDPs. From formulation to commercialization, we ensure high-quality, cost-effective production, regulatory compliance, and operational efficiency, delivering high quality products for respiratory drug delivery with a focus on innovation and reliability. More Info
